Latest news

Adalvo is pleased to announce the addition of Obeticholic Acid Tablets to our product Portfolio, a niche orphan product with strong growth potential.

We at Adalvo continue to strengthen our comprehensive arthritis medication portfolio, covering a unique selection for this indication. Arthritis is the swelling and tenderness of one or more joints. The...

One of our key targets is to deliver a diversified and competitive portfolio and support our partners in every step of their journey. We offer an array of women’s health...

Adalvo is pleased to announce the addition of Edoxaban film coated tablets to our product Portfolio. Dossier readiness for Edoxaban is expected in Q1 2024. Our product is being developed...

Following the successful completion of the acquisition of our first brand, Onsolis, we are pleased to announce that Adalvo will start supply of the product.

Adalvo is delighted to announce the successful MA approval of Solifenacin + Tamsulosin in various EU markets.

Adalvo is pleased to announce that it has entered into a strategic partnership with an Australian based company, Actor Pharmaceuticals, to commercialize several pharmaceutical products within the Australian market.

Adalvo is pleased to announce the addition of Isavuconazole Oral and Injectable forms to our product Portfolio. Dossier readiness for these products is expected in Q1 2024.

Adalvo is delighted to announce the successful DCP approval of our Teriflunomide 14 mg film-coated divisible tablets.

Adalvo is pleased to announce the addition of Fidaxomicin Film Coated Tablets, to our Product Portfolio within the antibiotic line. Our product is being developed in collaboration with one...

One of our key targets is to deliver a diversified and competitive portfolio and support our partners in every step of their journey. In this respect, we are pleased to...

Adalvo is pleased to announce the addition of Brivaracetam film coated tablets, to our product Portfolio. We are currently working on dossier completion for this product, which is expected in...

Adalvo is delighted to announce that our partner, CellResearch Corporation (CRC), has successfully closed the first Phase I study in CorLiCyte®, a stem cell therapy derived from umbilical cord lining stem...

The core strategy of Adalvo’s portfolio is innovation and differentiation, which allows us to make unique products available in the market, and supports our partners to target unmet medical needs....

August commemorates Psoriasis Awareness month and is used as an opportunity to educate and inform on a range of topics varying from treatment, causes, triggers and management of the inflammatory...

Adalvo is pleased to announce that we have signed an exclusive licensing agreement with Hikma Pharmaceuticals PLC (Hikma), a multinational pharmaceutical company, to commercialise a nasal spray indicated in the treatment...

We at Adalvo continue to strengthen our comprehensive pain management portfolio, covering a unique selection of products conducive to this indication.

Adalvo is very proud to announce that our dossier for Pregabalin ER tablets has been submitted successfully. Pregabalin is a backbone medication indicated in the treatment of Neuropathic pain.

We are pleased to announce that our dossier submission for Eribulin solution for injection, 0.44mg/ml has been completed.

Adalvo is pleased to announce our successful DCP closure for Fulvestrant pre-filled injection. Our product is a fully EU compliant generic version of Faslodex, which is a widely used drug,...

Adalvo is thrilled to announce the acquisition of our first branded product, Onsolis® after concluding a deal with a reputable US based specialty pharmaceutical Company, who originally owned the product....